Search

Your search keyword '"Varela-Moreira, Aida"' showing total 38 results
Start Over Author "Varela-Moreira, Aida"
38 results on '"Varela-Moreira, Aida"'

7. Evaluation of paclitaxel-loaded polymeric nanoparticles in 3D tumor model: impact of tumor stroma on penetration and efficacy

Author

Chirurgie, Afd Pharmaceutics, Pharmaceutics, Locomotion - Surgery (CA), Priwitaningrum, Dwi L., Pednekar, Kunal, Gabriël, Alexandros V., Varela-Moreira, Aida A., Le Gac, Severine, Vellekoop, Ivo, Storm, Gert, Hennink, Wim E., Prakash, Jai, Chirurgie, Afd Pharmaceutics, Pharmaceutics, Locomotion - Surgery (CA), Priwitaningrum, Dwi L., Pednekar, Kunal, Gabriël, Alexandros V., Varela-Moreira, Aida A., Le Gac, Severine, Vellekoop, Ivo, Storm, Gert, Hennink, Wim E., and Prakash, Jai

Published
2023

8. Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression

Author

Brandmeier, Lisa, primary, Ecker, Veronika, additional, Stumpf, Martina, additional, Giansanti, Piero, additional, Varela Moreira, Aida, additional, Pfeuffer, Lisa, additional, Fens, Marcel, additional, Lu, Junyan, additional, Küster, Bernhard, additional, Engleitner, Thomas, additional, Heidegger, Simon, additional, Ringshausen, Ingo, additional, Zenz, Thorsten, additional, Wendtner, Clemens-Martin, additional, Müschen, Markus, additional, Ruland, Jürgen, additional, and Buchner, Maike, additional

Published
2022
Full Text
View/download PDF

9. Utilizing in vitro drug release assays to predict in vivo drug retention in micelles

Author

Varela-Moreira, Aida, van Leur, Heleen, Krijgsman, Danielle, Ecker, Veronika, Braun, Martina, Buchner, Maike, Fens, Marcel H.A.M., Hennink, Wim E., Schiffelers, Raymond M., Varela-Moreira, Aida, van Leur, Heleen, Krijgsman, Danielle, Ecker, Veronika, Braun, Martina, Buchner, Maike, Fens, Marcel H.A.M., Hennink, Wim E., and Schiffelers, Raymond M.

Abstract

In the present work, we aim at developing an in vitro release assay to predict circulation times of hydrophobic drugs loaded into polymeric micelles (PM), upon intravenous (i.v.) administration. PM based on poly (ethylene glycol)-b-poly (N-2-benzoyloxypropyl methacrylamide) (mPEG-b-p(HPMA-Bz)) block copolymer were loaded with a panel of hydrophobic anti-cancer drugs and characterized for size, loading efficiency and release profile in different release media. Circulation times in mice of two selected drugs loaded in PM were evaluated and compared to the in vitro release profile. Release of drugs from PM was evaluated over 7 days in PBS containing Triton X-100 and in PBS containing albumin at physiological concentration (40 g/L). The results were utilized to identify crucial molecular features of the studied hydrophobic drugs leading to better micellar retention. For the best and the worst retained drugs in the in vitro assays (ABT-737 and BCI, respectively), the circulation of free and entrapped drugs into PM was examined after i.v. administration in mice. We found in vivo drug retention at 24 h post-injection similar to the retention found in the in vitro assays. This demonstrates that in vitro release assay in buffers supplemented with albumin, and to a lesser degree Triton X-100, can be employed to predict the in vivo circulation kinetics of drugs loaded in PM. Utilizing media containing acceptor molecules for hydrophobic compounds, provide a first screen to understand the stability of drug-loaded PM in the circulation and, therefore, can contribute to the reduction of animals used for circulation kinetics studies.

Published
2022

10. Utilizing in vitro drug release assays to predict in vivo drug retention in micelles

Author

Chirurgie, Afd Pharmaceutics, Pharmaceutics, Varela-Moreira, Aida, van Leur, Heleen, Krijgsman, Danielle, Ecker, Veronika, Braun, Martina, Buchner, Maike, Fens, Marcel H.A.M., Hennink, Wim E., Schiffelers, Raymond M., Chirurgie, Afd Pharmaceutics, Pharmaceutics, Varela-Moreira, Aida, van Leur, Heleen, Krijgsman, Danielle, Ecker, Veronika, Braun, Martina, Buchner, Maike, Fens, Marcel H.A.M., Hennink, Wim E., and Schiffelers, Raymond M.

Published
2022

11. Utilizing in vitro drug release assays to predict in vivo drug retention in micelles

Author

CDL Nanomedicine, CMM Groep Vercoulen, Cancer, Centraal Diagnostisch Laboratorium, Circulatory Health, Varela-Moreira, Aida, van Leur, Heleen, Krijgsman, Danielle, Ecker, Veronika, Braun, Martina, Buchner, Maike, Fens, Marcel H A M, Hennink, Wim E, Schiffelers, Raymond M, CDL Nanomedicine, CMM Groep Vercoulen, Cancer, Centraal Diagnostisch Laboratorium, Circulatory Health, Varela-Moreira, Aida, van Leur, Heleen, Krijgsman, Danielle, Ecker, Veronika, Braun, Martina, Buchner, Maike, Fens, Marcel H A M, Hennink, Wim E, and Schiffelers, Raymond M

Published
2022

15. Selective Inhibition of Class II HDAC Isoforms 4 and 5 Provides a Promising Therapeutic Intervention for MLL-Rearranged Acute Lymphoblastic Leukemia in Infants

Author

Verbeek, Tamara C.A.I., primary, Arentsen-Peters, Susan, additional, Garrido Castro, Patricia, additional, Pinhancos, Sandra, additional, Vrenken, Kirsten, additional, Varela-Moreira, Aida, additional, Dolman, M. Emmy, additional, Koopmans, Bianca, additional, Pieters, Rob, additional, and Stam, Ronald W., additional

Published
2021
Full Text
View/download PDF

17. Effect of formulation and processing parameters on the size of mPEG-b-p(HPMA-Bz) polymeric micelles

Author

Bagheri, Mahsa, Bresseleers, Jaleesa, Varela Moreira, Aida, Sandre, Olivier, Meeuwissen, Silvie A, Schiffelers, Raymond M, Metselaar, Josbert M, van Nostrum, Cornelus F, van Hest, Jan C M, Hennink, Wim E, Afd Pharmaceutics, Pharmaceutics, Department of Pharmaceutics Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University [Utrecht], ChemConnection BV, Eindhoven University of Technology [Eindhoven] (TU/e), University Medical Center [Utrecht], Laboratoire de Chimie des Polymères Organiques (LCPO), Centre National de la Recherche Scientifique (CNRS)-Institut Polytechnique de Bordeaux-Ecole Nationale Supérieure de Chimie, de Biologie et de Physique (ENSCBP)-Université de Bordeaux (UB)-Institut de Chimie du CNRS (INC), Team 3 LCPO : Polymer Self-Assembly & Life Sciences, Centre National de la Recherche Scientifique (CNRS)-Institut Polytechnique de Bordeaux-Ecole Nationale Supérieure de Chimie, de Biologie et de Physique (ENSCBP)-Université de Bordeaux (UB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut Polytechnique de Bordeaux-Ecole Nationale Supérieure de Chimie, de Biologie et de Physique (ENSCBP)-Université de Bordeaux (UB)-Institut de Chimie du CNRS (INC), RWTH University Clinic, HighTech Systems & Materials (HTSM) grant number 13312 from the Netherlands Organisation for Scientific Research (NWO), European Project: 676137,H2020,H2020-MSCA-ITN-2015,NANOMED(2016), Afd Pharmaceutics, Pharmaceutics, Bio-Organic Chemistry, Université de Bordeaux (UB)-Ecole Nationale Supérieure de Chimie, de Biologie et de Physique (ENSCBP)-Institut Polytechnique de Bordeaux-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), and Université de Bordeaux (UB)-Ecole Nationale Supérieure de Chimie, de Biologie et de Physique (ENSCBP)-Institut Polytechnique de Bordeaux-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB)-Ecole Nationale Supérieure de Chimie, de Biologie et de Physique (ENSCBP)-Institut Polytechnique de Bordeaux-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)

Subjects
02 engineering and technology, Degree of polymerization, 010402 general chemistry, 01 natural sciences, Micelle, Article, chemistry.chemical_compound, Dynamic light scattering, Electrochemistry, Copolymer, Methacrylamide, General Materials Science, Spectroscopy, ComputingMilieux_MISCELLANEOUS, chemistry.chemical_classification, Aqueous two-phase system, Surfaces and Interfaces, Polymer, 021001 nanoscience & nanotechnology, Condensed Matter Physics, 3. Good health, 0104 chemical sciences, [CHIM.POLY]Chemical Sciences/Polymers, chemistry, Chemical engineering, 0210 nano-technology, Ethylene glycol, [PHYS.COND.CM-SCM]Physics [physics]/Condensed Matter [cond-mat]/Soft Condensed Matter [cond-mat.soft]
Abstract

Micelles composed of block copolymers of poly(ethylene glycol)-b-poly(N-2-benzoyloxypropyl methacrylamide) (mPEG-b-p(HPMA-Bz)) have shown great promise as drug-delivery carriers due to their excellent stability and high loading capacity. In the present study, parameters influencing micelle size were investigated to tailor sizes in the range of 25-100 nm. Micelles were prepared by a nanoprecipitation method, and their size was modulated by the block copolymer properties such as molecular weight, their hydrophilic-to-hydrophobic ratio, homopolymer content, as well as formulation and processing parameters. It was shown that the micelles have a core-shell structure using a combination of dynamic light scattering and transmission electron microscopy analysis. By varying the degree of polymerization of the hydrophobic block (NB) between 68 and 10, at a fixed hydrophilic block mPEG5k (NA = 114), it was shown that the hydrophobic core of the micelle was collapsed following the power law of (NB × Nagg)1/3. Further, the calculated brush height was similar for all the micelles examined (10 nm), indicating that crew-cut micelles were made. Both addition of homopolymer and preparation of micelles at lower concentrations or lower rates of addition of the organic solvent to the aqueous phase increased the size of micelles due to partitioning of the hydrophobic homopolymer chains to the core of the micelles and lower nucleation rates, respectively. Furthermore, it was shown that by using different solvents, the size of the micelles substantially changed. The use of acetone, acetonitrile, ethanol, tetrahydrofuran, and dioxane resulted in micelles in the size range of 45-60 nm after removal of the organic solvents. The use of dimethylformamide and dimethylsulfoxide led to markedly larger sizes of 75 and 180 nm, respectively. In conclusion, the results show that by modulating polymer properties and processing conditions, micelles with tailorable sizes can be obtained.

Published
2018
Full Text
View/download PDF

18. Systematic evaluation of design features enables efficient selection of Π electron-stabilized polymeric micelles

Author

Sheybanifard, Maryam, primary, Beztsinna, Nataliia, additional, Bagheri, Mahsa, additional, Buhl, Eva Miriam, additional, Bresseleers, Jaleesa, additional, Varela-Moreira, Aida, additional, Shi, Yang, additional, van Nostrum, Cornelus F., additional, van der Pluijm, Gabri, additional, Storm, Gert, additional, Hennink, Wim E., additional, Lammers, Twan, additional, and Metselaar, Josbert M., additional

Published
2020
Full Text
View/download PDF

19. This title is unavailable for guests, please login to see more information.

Author

Sheybanifard, Maryam, Beztsinna, Nataliia, Bagheri, Mahsa, Buhl, Eva Miriam, Bresseleers, Jaleesa, Varela-Moreira, Aida, Shi, Yang, van Nostrum, Cornelus F, van der Pluijm, Gabri, Storm, Gert, Hennink, Wim E, Lammers, Twan, Metselaar, Josbert M, Sheybanifard, Maryam, Beztsinna, Nataliia, Bagheri, Mahsa, Buhl, Eva Miriam, Bresseleers, Jaleesa, Varela-Moreira, Aida, Shi, Yang, van Nostrum, Cornelus F, van der Pluijm, Gabri, Storm, Gert, Hennink, Wim E, Lammers, Twan, and Metselaar, Josbert M

Abstract

Polymeric micelles (PM) based on poly(ethylene glycol)-b-poly(N-2-benzoyloxypropyl methacrylamide) (mPEG-b-p(HPMA-Bz)) loaded with paclitaxel (PTX-PM) have shown promising results in overcoming the suboptimal efficacy/toxicity profile of paclitaxel. To get insight into the stability of PTX-PM formulations upon storage and to optimize their in vivo tumor-targeted drug delivery properties, we set out to identify a lead PTX-PM formulation with the optimal polymer composition. To this end, PM based on four different mPEG5k-b-p(HPMA-Bz) block copolymers with varying molecular weight of the hydrophobic block (17-3 kDa) were loaded with different amounts of PTX. The hydrodynamic diameter was 52 ± 1 nm for PM prepared using polymers with longer hydrophobic blocks (mPEG5k-b-p(HPMA-Bz)17k and mPEG5k-b-p(HPMA-Bz)10k) and 39 ± 1 nm for PM composed of polymers with shorter hydrophobic blocks (mPEG5k-b-p(HPMA-Bz)5k and mPEG5k-b-p(HPMA-Bz)3k). The best storage stability and the slowest PTX release was observed for PM with larger hydrophobic blocks. On the other hand, smaller sized PM of shorter mPEG5k-b-p(HPMA-Bz)5k showed a better tumor penetration in 3D spheroids. Considering better drug retention capacity of the mPEG5k-b-p(HPMA-Bz)17k and smaller size of the mPEG5k-b-p(HPMA-Bz)5k as two desirable design features, we argue that PM based on these two polymers are the lead candidates for further in vivo studies.

Published
2020

21. This title is unavailable for guests, please login to see more information.

Author

Afd Pharmaceutics, Pharmaceutics, Sheybanifard, Maryam, Beztsinna, Nataliia, Bagheri, Mahsa, Buhl, Eva Miriam, Bresseleers, Jaleesa, Varela-Moreira, Aida, Shi, Yang, van Nostrum, Cornelus F, van der Pluijm, Gabri, Storm, Gert, Hennink, Wim E, Lammers, Twan, Metselaar, Josbert M, Afd Pharmaceutics, Pharmaceutics, Sheybanifard, Maryam, Beztsinna, Nataliia, Bagheri, Mahsa, Buhl, Eva Miriam, Bresseleers, Jaleesa, Varela-Moreira, Aida, Shi, Yang, van Nostrum, Cornelus F, van der Pluijm, Gabri, Storm, Gert, Hennink, Wim E, Lammers, Twan, and Metselaar, Josbert M

Published
2020

23. Systematic evaluation of design features enables efficient selection of Π electron-stabilized polymeric micelles

Author

Sheybanifard, Maryam, Beztsinna, Nataliia, Bagheri, Mahsa, Buhl, Eva Miriam, Bresseleers, Jaleesa, Varela-Moreira, Aida, Shi, Yang, van Nostrum, Cornelus F, van der Pluijm, Gabri, Storm, Gert, Hennink, Wim E, Lammers, Twan, Metselaar, Josbert M, Sheybanifard, Maryam, Beztsinna, Nataliia, Bagheri, Mahsa, Buhl, Eva Miriam, Bresseleers, Jaleesa, Varela-Moreira, Aida, Shi, Yang, van Nostrum, Cornelus F, van der Pluijm, Gabri, Storm, Gert, Hennink, Wim E, Lammers, Twan, and Metselaar, Josbert M

Published
2020

24. Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model

Author

Afd Pharmaceutics, Dep Farmaceutische wetenschappen, Pharmaceutics, Varela-Moreira, Aida, van Straten, Demian, van Leur, Heleen F, Ruiter, Ruud W J, Deshantri, Anil K, Hennink, Wim E, Fens, Marcel H A M, Groen, Richard W J, Schiffelers, Raymond M, Afd Pharmaceutics, Dep Farmaceutische wetenschappen, Pharmaceutics, Varela-Moreira, Aida, van Straten, Demian, van Leur, Heleen F, Ruiter, Ruud W J, Deshantri, Anil K, Hennink, Wim E, Fens, Marcel H A M, Groen, Richard W J, and Schiffelers, Raymond M

Published
2020

25. Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model

Author

CDL Nanomedicine, CDL Staf Research, Cancer, CDL Cluster Onderzoek en Onderwijs, Circulatory Health, Varela-Moreira, Aida, van Straten, Demian, van Leur, Heleen F, Ruiter, Ruud W J, Deshantri, Anil K, Hennink, Wim E, Fens, Marcel H A M, Groen, Richard W J, Schiffelers, Raymond M, CDL Nanomedicine, CDL Staf Research, Cancer, CDL Cluster Onderzoek en Onderwijs, Circulatory Health, Varela-Moreira, Aida, van Straten, Demian, van Leur, Heleen F, Ruiter, Ruud W J, Deshantri, Anil K, Hennink, Wim E, Fens, Marcel H A M, Groen, Richard W J, and Schiffelers, Raymond M

Published
2020

26. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma

Author

Deshantri, Anil K, Fens, Marcel H, Ruiter, Ruud W J, Metselaar, Josbert M, Storm, Gert, van Bloois, Louis, Varela-Moreira, Aida, Mandhane, Sanjay N, Mutis, Tuna, Martens, Anton C M, Groen, Richard W J, Schiffelers, Raymond M, Deshantri, Anil K, Fens, Marcel H, Ruiter, Ruud W J, Metselaar, Josbert M, Storm, Gert, van Bloois, Louis, Varela-Moreira, Aida, Mandhane, Sanjay N, Mutis, Tuna, Martens, Anton C M, Groen, Richard W J, and Schiffelers, Raymond M

Abstract

Glucocorticoids are the cornerstone in the clinic for treatment of hematological malignancies, including multiple myeloma. Nevertheless, poor pharmacokinetic properties of glucocorticoids require high and frequent dosing with the off-target adverse effects defining the maximum dose. Recently, nanomedicine formulations of glucocorticoids have been developed that improve the pharmacokinetic profile, limit adverse effects and improve solid tumor accumulation. Multiple myeloma is a hematological malignancy characterized by uncontrolled growth of plasma cells. These tumors initiate increased angiogenesis and microvessel density in the bone marrow, which might be exploited using nanomedicines, such as liposomes. Nano-sized particles can accumulate as a result of the increased vascular leakiness at the bone marrow tumor lesions. Pre-clinical screening of novel anti-myeloma therapeutics in vivo requires a suitable animal model that represents key features of the disease. In this study, we show that fluorescently labeled long circulating liposomes were found in plasma up to 24 h after injection in an advanced human-mouse hybrid model of multiple myeloma. Besides the organs involved in clearance, liposomes were also found to accumulate in tumor bearing human-bone scaffolds. The therapeutic efficacy of liposomal dexamethasone phosphate was evaluated in this model showing strong tumor growth inhibition while free drug being ineffective at an equivalent dose (4 mg/kg) regimen. The liposomal formulation slightly reduced total body weight of myeloma-bearing mice during the course of treatment, which appeared reversible when treatment was stopped. Liposomal dexamethasone could be further developed as monotherapy or could fit in with existing therapy regimens to improve therapeutic outcomes for multiple myeloma.

Published
2019

27. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma

Author

Afd Pharmaceutics, Pharmaceutics, Deshantri, Anil K, Fens, Marcel H, Ruiter, Ruud W J, Metselaar, Josbert M, Storm, Gert, van Bloois, Louis, Varela-Moreira, Aida, Mandhane, Sanjay N, Mutis, Tuna, Martens, Anton C M, Groen, Richard W J, Schiffelers, Raymond M, Afd Pharmaceutics, Pharmaceutics, Deshantri, Anil K, Fens, Marcel H, Ruiter, Ruud W J, Metselaar, Josbert M, Storm, Gert, van Bloois, Louis, Varela-Moreira, Aida, Mandhane, Sanjay N, Mutis, Tuna, Martens, Anton C M, Groen, Richard W J, and Schiffelers, Raymond M

Published
2019

28. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma

Author

CDL Nanomedicine, Circulatory Health, Cancer, CDL Cluster Onderzoek en Onderwijs, Deshantri, Anil K., Fens, Marcel H., Ruiter, Ruud W. J., Metselaar, Josbert M., Storm, Gert, van Bloois, Louis, Varela-Moreira, Aida, Mandhane, Sanjay N., Mutis, Tuna, Martens, Anton C. M., Groen, Richard W. J., Schiffelers, Raymond M., CDL Nanomedicine, Circulatory Health, Cancer, CDL Cluster Onderzoek en Onderwijs, Deshantri, Anil K., Fens, Marcel H., Ruiter, Ruud W. J., Metselaar, Josbert M., Storm, Gert, van Bloois, Louis, Varela-Moreira, Aida, Mandhane, Sanjay N., Mutis, Tuna, Martens, Anton C. M., Groen, Richard W. J., and Schiffelers, Raymond M.

Published
2019

29. Nanomedicines for the treatment of hematological malignancies

Author

Deshantri, Anil K, Varela Moreira, Aida, Ecker, Veronika, Mandhane, Sanjay N, Schiffelers, Raymond M, Buchner, Maike, Fens, Marcel H A M, Deshantri, Anil K, Varela Moreira, Aida, Ecker, Veronika, Mandhane, Sanjay N, Schiffelers, Raymond M, Buchner, Maike, and Fens, Marcel H A M

Abstract

Hematological malignancies (HM) are a collection of malignant transformations originating from cells in the primary or secondary lymphoid organs. Leukemia, lymphoma, and multiple myeloma comprise the three major types of HM. Current treatment consists of bone marrow transplantation, radiotherapy, immunotherapy and chemotherapy. Although, many chemotherapeutic drugs are clinically available for the treatment of HM, the use of these agents is limited due to dose-related toxicity and lack of specificity to tumor tissue. Moreover, the poor pharmacokinetic profile of most of the chemotherapeutics requires high dosage and frequent administration to maintain therapeutic levels at the target site, both increasing adverse effects. This underlines an urgent need for a suitable drug delivery system to improve efficacy, safety, and pharmacokinetic properties of conventional therapeutics. Nanomedicines have proven to enhance these properties for anticancer therapeutics. The most extensively studied nanomedicine systems are lipid-based nanoparticles and polymeric nanoparticles. Typically, nanomedicines are small sub-micron sized particles in the size range of 20-200 nm. The biocompatible and biodegradable nature of nanomedicines makes them attractive vehicles to improve drug delivery. Their small size allows them to extravasate and accumulate at malignant sites passively by means of the enhanced permeability and retention (EPR) effect, resulting from rapid angiogenesis and inflammation. Moreover, the specificity to the target tissue can be further enhanced by surface modification of nanoparticles. This review describes currently available therapies as well as limitations and potential advantages of nanomedicine formulations for treatment of various types of HM. Additionally, recent investigational and approved nanomedicine formulations and their limited applications in HM are discussed.

Published
2018

30. The Effect of Formulation and Processing Parameters on the Size of mPEG-b-p(HPMA-Bz) Polymeric Micelles

Author

Bagheri, Mahsa, Bresseleers, Jaleesa, Varela Moreira, Aida, Sandre, Olivier, Meeuwissen, Silvie A, Schiffelers, Raymond M, Metselaar, Josbert M, van Nostrum, Cornelus F, van Hest, Jan C M, Hennink, Wim E, Bagheri, Mahsa, Bresseleers, Jaleesa, Varela Moreira, Aida, Sandre, Olivier, Meeuwissen, Silvie A, Schiffelers, Raymond M, Metselaar, Josbert M, van Nostrum, Cornelus F, van Hest, Jan C M, and Hennink, Wim E

Abstract

Micelles composed of block copolymers of poly(ethylene glycol)-b-poly(N-2-benzoyloxypropyl methacrylamide) (mPEG-b-p(HPMA-Bz)) have shown great promise as drug delivery carriers due to their excellent stability and high loading capacity. In the present study, parameters influencing micelle size were investigated to tailor sizes in the range of 25 to 100 nm. Micelles were prepared by a nanoprecipitation method and their size was modulated by the block copolymer properties such as molecular weight, their hydrophilic to hydrophobic ratio, homopolymer content, as well as formulation and processing parameters. It was shown that the micelles have a core-shell structure using a combination of dynamic light scattering and transmission electron microscopy analysis. By varying the degree of polymerization of the hydrophobic block (NB) between 68 and 10, at a fixed hydrophilic block mPEG5K (NA=114), it was shown that the hydrophobic core of the micelle was collapsed following the power law of (NB×Nagg)1/3. Further, the calculated brush height was similar for all the micelles examined (10 nm), indicating that crew-cut micelles were made. Both addition of homopolymer and preparation of micelles at lower concentrations or lower rates of addition of the organic solvent to the aqueous phase increased the size of micelles due to partitioning of the hydrophobic homopolymer chains to the core of the micelles and lower nucleation rates, respectively. Furthermore, it was shown that by using different solvents, the size of the micelles substantially changed. The use of acetone, acetonitrile, ethanol, THF and dioxane, resulted in micelles in the size range from 45 to 60 nm after removal of the organic solvents. The use of DMF and DMSO led to markedly larger sizes of 75 and 180 nm respectively. In conclusion, the results show that by modulating polymer properties and processing conditions, micelles with tailorable sizes can be obtained.

Published
2018

31. Nanomedicines for the treatment of hematological malignancies

Author

Afd Pharmaceutics, Pharmaceutics, Deshantri, Anil K, Varela Moreira, Aida, Ecker, Veronika, Mandhane, Sanjay N, Schiffelers, Raymond M, Buchner, Maike, Fens, Marcel H A M, Afd Pharmaceutics, Pharmaceutics, Deshantri, Anil K, Varela Moreira, Aida, Ecker, Veronika, Mandhane, Sanjay N, Schiffelers, Raymond M, Buchner, Maike, and Fens, Marcel H A M

Published
2018

32. The Effect of Formulation and Processing Parameters on the Size of mPEG-b-p(HPMA-Bz) Polymeric Micelles

Author

Afd Pharmaceutics, Pharmaceutics, Bagheri, Mahsa, Bresseleers, Jaleesa, Varela Moreira, Aida, Sandre, Olivier, Meeuwissen, Silvie A, Schiffelers, Raymond M, Metselaar, Josbert M, van Nostrum, Cornelus F, van Hest, Jan C M, Hennink, Wim E, Afd Pharmaceutics, Pharmaceutics, Bagheri, Mahsa, Bresseleers, Jaleesa, Varela Moreira, Aida, Sandre, Olivier, Meeuwissen, Silvie A, Schiffelers, Raymond M, Metselaar, Josbert M, van Nostrum, Cornelus F, van Hest, Jan C M, and Hennink, Wim E

Published
2018

33. Nanomedicines for the treatment of hematological malignancies

Author

Circulatory Health, CDL Nanomedicine, Cancer, LKCH Research Platelet Biology, CDL Cluster Onderzoek en Onderwijs, Deshantri, Anil K., Varela Moreira, Aida, Ecker, Veronika, Mandhane, Sanjay N., Schiffelers, Raymond M., Buchner, Maike, Fens, Marcel H.A.M., Circulatory Health, CDL Nanomedicine, Cancer, LKCH Research Platelet Biology, CDL Cluster Onderzoek en Onderwijs, Deshantri, Anil K., Varela Moreira, Aida, Ecker, Veronika, Mandhane, Sanjay N., Schiffelers, Raymond M., Buchner, Maike, and Fens, Marcel H.A.M.

Published
2018

34. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis

Author

Afd Pharmaceutics, Pharmaceutics, Alaarg, Amr, Senders, Max L., Varela-Moreira, Aida, Pérez-Medina, Carlos, Zhao, Yiming, Tang, Jun, Fay, Francois, Reiner, Thomas, Fayad, Zahi A., Hennink, Wim E., Metselaar, Josbert M., Mulder, Willem J.M., Storm, G, Afd Pharmaceutics, Pharmaceutics, Alaarg, Amr, Senders, Max L., Varela-Moreira, Aida, Pérez-Medina, Carlos, Zhao, Yiming, Tang, Jun, Fay, Francois, Reiner, Thomas, Fayad, Zahi A., Hennink, Wim E., Metselaar, Josbert M., Mulder, Willem J.M., and Storm, G

Published
2017

37. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis

Author

Alaarg, Amr, Senders, Max L., Varela-Moreira, Aida, Pérez-Medina, Carlos, Zhao, Yiming, Tang, Jun, Fay, Francois, Reiner, Thomas, Fayad, Zahi A., Hennink, Wim E., Metselaar, Josbert M., Mulder, Willem J. M., and Storm, Gert

Subjects
3. Good health
Abstract

Journal of controlled release 262, 47-57 (2017). doi:10.1016/j.jconrel.2017.07.013, Published by Elsevier, New York, NY [u.a.]

38. Effect of Formulation and Processing Parameters on the Size of mPEG-b-p(HPMA-Bz) Polymeric Micelles

Author

Bagheri, Mahsa, Bresseleers, Jaleesa, Varela-Moreira, Aida, Sandre, Olivier, Meeuwissen, Silvie A., Schiffelers, Raymond M., Metselaar, Josbert M., Van Nostrum, Cornelus F., Van Hest, Jan C. M., and Hennink, Wim E.

Subjects
3. Good health
Abstract

Langmuir : the ACS journal of surfaces and colloids 34(50), 15495-15506 (2018). doi:10.1021/acs.langmuir.8b03576, Published by ACS Publ., Washington, DC

Catalog

Books, media, physical & digital resources
See catalog results